THE GENERAL HOSPITAL CORPORATION d/b/a MASSACHUSETTS GENERAL HOSPITAL Patent applications |
Patent application number | Title | Published |
20160128976 | ANTIFUGETACTIC AGENTS FOR THE TREATMENT OF CANCERS - This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response. | 05-12-2016 |
20160128975 | ANTIFUGETACTIC AGENTS FOR THE TREATMENT OF LUNG CANCER - This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response. | 05-12-2016 |
20160122405 | HOMEODOMAIN FUSION PROTEINS AND USES THEREOF - Provided herein are fusion proteins comprising a homeodomain fusion protein domain and a transcription modulator domain for treatment of various diseases or disorders such as cancer. The homeodomain fusion protein domain binds to a target gene and the transcription modulator domain either activates or represses gene transcription. The present invention also relates to polynucleotides encoding the fusion proteins, vectors comprising the polynucleotides, cells comprising the polynucleotides, vectors, or fusion proteins. Also provided are methods of use and compositions for delivery of the fusion proteins. | 05-05-2016 |
20160113971 | Compositions of Microbiota and Methods Related Thereto - Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as | 04-28-2016 |
20160068885 | AGENTS PROVIDING CONTROLS AND STANDARDS FOR IMMUNOPRECIPITATION ASSAYS - Control agents for immunoprecipitation assays, methods of using the control agents and kits comprising the control agents are provided. | 03-10-2016 |
20150313890 | KINASE INHIBITORS AND METHODS OF USE THEREOF - The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3α or GSK3β) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer. | 11-05-2015 |
20150284356 | COMPOUNDS FOR TREATING INFECTIOUS DISEASES - The present invention provides compounds of Formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting fungal or parasitic growth. The compounds are useful as inhibitors of glycosylphosphatidylinositol (GPI)-anchor biosynthesis, in particular, as inhibitors of fungal Gwt1 activity. The present invention further provides methods of using the compounds described herein for treating fungal or parasitic infections. The compounds can also be used as biological probes to study the effects of inhibiting Gwt1 activity. | 10-08-2015 |
20150252364 | COMPOSITIONS AND METHODS FOR MODULATING SMN GENE FAMILY EXPRESSION - Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2 that comprises exon 7. Methods for modulating expression of SMN1 or SMN2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of SMN1 or SMN2. | 09-10-2015 |
20150218560 | COMPOSITIONS FOR MODULATING GENE EXPRESSION - Aspects of the invention provide methods for selecting a candidate oligonucleotide for activating expression of a target gene. Further aspects of the invention provide methods of selecting a set of oligonucleotides that is enriched in oligonucleotides that activate expression of a target gene. Further aspects provide single stranded oligonucleotides that modulate gene expression and compositions and kits comprising the same. Methods for modulating gene expression using the single stranded oligonucleotides are also provided. | 08-06-2015 |
20150218259 | ANTIBODIES TO CROSS-LINKED AMYLOID BETA OLIGOMERS - The invention relates to antibodies that bind cross-linked amyloid β oligomers, and methods for using such antibodies for diagnosis and treatment of Alzheimer's disease. | 08-06-2015 |
20150191722 | COMPOSITIONS AND METHODS FOR MODULATING APOA1 AND ABCA1 EXPRESSION - Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of APOA1 or ABCA1. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of APOA1 or ABCA1. Methods for modulating expression of APOA1 or ABCA1 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of APOA1 or ABCA1. | 07-09-2015 |
20150191427 | INHIBITORS OF HISTONE DEACETYLASE - The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X | 07-09-2015 |
20150191417 | ANTI-PROLIFERATIVE COMPOUNDS AND USES THEREOF - The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, tautomers, stereoisomers, solvates, hydrates, polymorphs, and compositions thereof. Also provided are methods and kits involving the inventive compounds for treating proliferative diseases (e.g., cancers (e.g., breast cancer, prostate cancer, lung cancer, and ovarian cancer), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound of the invention may enhance the anti-tumor immune response by inhibiting or eliminating the immune suppression mediated by immune suppressor myeloid cells (MDSCs), inducing apoptosis, and/or inhibit or down-regulate proteins (e.g., epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), X-linked inhibitor of apoptosis protein (XIAP), and heat shock protein 90 (Hsp90)) in the subject. | 07-09-2015 |
20150190411 | ACTIVATION OF HISTONE DEACETYLASE 1 (HDAC1) PROTECTS AGAINST DNA DAMAGE AND INCREASES NEURONAL SURVIVAL - The invention provides methods and compounds for the treatment of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), traumatic brain injury, ischemic brain injury or a stroke. In one aspect the compounds are HDAC1 activators. Exemplary HDAC1 activators include metal chelators, iron chelators, deferoxamin, flavonoids, compounds comprising a catechol moity, ginkgetin K, Chembridge 5104434, sciadopilysin, tetrahydrogamboic acid, TAM-11, LY 235959, CGS 19755, SK&F 97541, etidronic acid, levonordefrin, methyldopa, ampicillin trihydrate, D-aspartic acid, gamma-D-glutamylaminomethylsulfonic acid, phenazopyridine to hydrochloride, oxalamine citrate salt, podophyllotoxin, SK&F 97541, (+−)-4-amino-3-(5-chloro-2-thienyl)-butanoic acid, (RS)-(tetrazol-5-yl) glycine, R(+)-SKF-81297, gambogic acid, and derivatives thereof. | 07-09-2015 |
20150174138 | DIAGNOSTIC AND TREATMENT METHODS IN SUBJECTS HAVING OR AT RISK OF DEVELOPING RESISTANCE TO CANCER THERAPY - The invention relates to methods of treatment and diagnosis of subjects with cancer. In some aspects, the invention relates to methods of treatment and diagnosis of subjects with cancer, wherein the cancer is characterized by a Notch pathway activation mutation or by resistance to a Notch pathway inhibitor. | 06-25-2015 |
20150159161 | COMPOSITIONS AND METHODS FOR MODULATING PTEN EXPRESSION - Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of PTEN. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of PTEN. Methods for modulating expression of PTEN using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of PTEN. | 06-11-2015 |
20150159160 | COMPOSITIONS AND METHODS FOR MODULATING ATP2A2 EXPRESSION - Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of ATP2A2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of ATP2A2. Methods for modulating expression of ATP2A2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of ATP2A2. | 06-11-2015 |
20150152410 | COMPOSITIONS AND METHODS FOR MODULATING MECP2 EXPRESSION - Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of MECP2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of MECP2. Methods for modulating expression of MECP2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of MECP2. | 06-04-2015 |
20150141320 | COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION - Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of a target gene. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of a target gene. Methods for modulating expression of a target gene using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of a target gene. | 05-21-2015 |
20150133528 | COMPOSITIONS AND METHODS FOR MODULATING HEMOGLOBIN GENE FAMILY EXPRESSION - Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes (HBB, HBD, HBE1, HBG1 or HBG2). Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes. Methods for modulating expression of hemoglobin genes using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of hemoglobin genes. | 05-14-2015 |
20150133396 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS - Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively. | 05-14-2015 |
20150133362 | COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION - Aspects of the invention provide methods for selecting a candidate oligonucleotide for activating expression of a target gene. Further aspects of the invention provide methods of selecting a set of oligonucleotides that is enriched in oligonucleotides that activate expression of a target gene. Further aspects provide single stranded oligonucleotides that modulate gene expression and compositions and kits comprising the same. Methods for modulating gene expression using the single stranded oligonucleotides are also provided. | 05-14-2015 |
20150093802 | ZINC FINGER NUCLEASE FOR THE CFTR GENE AND METHODS OF USE THEREOF - The present invention provides new zinc finger proteins and zinc finger nuclease (ZFNs) that find particular using in repairing the cystic fibrosis transmembrane conductance regulator (CFTR) gene. | 04-02-2015 |
20150057297 | HALOFUGINOL DERIVATIVES AND THEIR USE IN COSMETIC AND PHARMACEUTICAL COMPOSITIONS - The present invention provides halofuginol, and derivatives and salts thereof, including diasteromerically enriched compositions thereof. The invention also provides pharmaceutical and cosmetic compositions thereof as well as methods for using halofuginol and derivatives thereof in treating chronic inflammatory diseases, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, viral infections, malaria, ischemic damage, transplant rejection, neurodegenerative diseases, T-cell neoplasms, and cosmetic conditions. | 02-26-2015 |
20140377267 | ANTIBODIES TO CROSS-LINKED AMYLOID BETA OLIGOMERS - The invention relates to antibodies that bind cross-linked amyloid β oligomers, and methods for using such antibodies for diagnosis and treatment of Alzheimer's disease. | 12-25-2014 |
20140296100 | METHODS FOR TREATING CANCER RESISTANT TO ERBB THERAPEUTICS - Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell. | 10-02-2014 |
20140288012 | METHODS FOR THE PREVENTION AND TREATMENT OF BURN INJURIES AND SECONDARY COMPLICATIONS - The disclosure relates to methods for treating a subject suffering from a burn injury or associated complications by administering to the subject an effective amount of an aromatic-cationic peptide. For example, a burn injury may be associated with distant pathophysiological effects, such as hypermetabolism, skeletal muscle dysfunction, and organ damage. The disclosure also relates to methods for protecting a subject from a burn injury by administering an effective amount of an aromatic-cationic peptide to a subject at risk of a burn injury. | 09-25-2014 |
20140199278 | BROWN ADIPOCYTE MODIFICATION - Methods and therapeutics are provided for treating metabolic disorders by increasing activation of brown adipose tissue. Generally, the methods and therapeutics can increase activation of brown adipose tissue to increase energy expenditure and induce weight loss. In one embodiment, a method for increasing activation of brown adipose tissue includes modifying brown adipocytes to express a gene that activates brown adipocytes, such as uncoupling protein 1. In another embodiment, a method for increasing brown adipose tissue activation includes increasing the number of brown adipocytes. This can be accomplished by inducing proliferation of adipocytes in vivo or expanding adipocytes ex vivo, transplanting adipocytes into brown adipose tissue depots or elsewhere and inducing differentiation of adipocyte progenitor cells, such as MSCs, adipocyte progenitor cells, pre-adipocytes and adipocyte precursor cells. | 07-17-2014 |
20140194937 | FASTENER - A fastener includes an elongate fastener body defining a longitudinal axis substantially central thereto. The fastener body has a continuous outer fastener shell laterally surrounding the longitudinal axis. The fastener shell longitudinally separates a fastener head end and a fastener tip end. A tool-engaging feature is provided on the fastener head end. A plurality of teeth are located on the fastener shell and extend substantially laterally outward from the longitudinally axis. The fastener shell is comprised of at least one undulate face and at least one substantially flat face. The plurality of teeth are located only on the undulate faces. Each tooth is longitudinally separated from adjacent teeth along an undulate face. A method of installing the fastener into a receiving structure is also described. | 07-10-2014 |
20140170221 | METHODS AND COMPOSITIONS FOR LOCALIZED DELIVERY OF AGENTS TO VIRALLY INFECTED CELLS AND TISSUES - The invention provides compositions and methods for delivering an agent to virally infected tissues and/or cells of a subject by conjugating agent-loaded nanoparticles to virus-specific T cells, such as cytotoxic T lymphocytes. The agent may be a latency-reversing drug (LRD), an antiviral agent and/or an agent that enhances cytotoxic efficacy of T lymphocytes. | 06-19-2014 |
20140107141 | KINASE INHIBITORS AND METHODS OF USE THEREOF - The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3α or GSK3β) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychriatic disorders, metabolic disorders, and cancer. | 04-17-2014 |
20140087999 | CLINICAL PREDICTORS OF WEIGHT LOSS - Methods and compositions are generally provided for treating metabolic disorders, e.g., obesity. One aspect discloses methods and compositions for obtaining a biological sample from the subject, evaluating the sample for the presence or absence of a genetic indicator, wherein the genetic indicator is selected from a single nucleotide polymorphism and a level of gene expression, and performing a first metabolic procedure if the genetic indicator is present, or performing an alternative second metabolic procedure if the genetic indicator is absent. One aspect discloses methods and compositions for obtaining a sample including deoxyribonucleic acids (DNA) from the subject, evaluating the DNA for an absence or presence of one or more genetic indicators and performing a first metabolic procedure or an alternative second metabolic procedure based on the absence or presence of the genetic indicator(s). Other aspects are also disclosed. | 03-27-2014 |
20140031647 | IN VIVO FLOW CYTOMETRY BASED ON CELLULAR AUTOFLUORESCENCE - The present invention generally provides methods and systems for performing in vivo flow cytometry by using blood vessels as flow chambers through which flowing cells can be monitored in a live subject in vivo without the need for withdrawing a blood sample. In some embodiments, one or more blood vessels are illuminated with radiation so as to cause a multi-photon excitation of an exogenous fluorophore that was previously introduced into the subject to label one or more cell types of interest. In some other embodiments, rather than utilizing an exogenous fluorophore, endogenous (intrinsic) cellular fluorescence can be employed for in vivo flow cytometry. The emission of fluorescence radiation from such fluorophores in response to the excitation can be detected and analyzed to obtain information regarding a cell type of interest. | 01-30-2014 |
20140030277 | IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF - This invention is directed to β-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The β-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety. | 01-30-2014 |
20140018767 | METHODS AND DEVICES FOR ACTIVATING BROWN ADIPOSE TISSUE WITH TARGETED SUBSTANCE DELIVERY - Methods and devices are provided for activating brown adipose tissue with targeted substance delivery. Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss and/or improved metabolic function. In one embodiment, a chemical configured to stimulate nerves that activate the BAT and/or to stimulate brown adipocytes directly can be delivered to a patient, thereby increasing thermogenesis in the BAT and inducing weight loss and/or improved metabolic function through energy expenditure. The chemical can be delivered to the patient locally and/or systemically to stimulate the nerves and/or the brown adipocytes. | 01-16-2014 |
20130336936 | CELL TRANSPLANTATION - The present invention provides polymers for use in preventing damage to the membranes of cells in fat grafts. Mixing of a triblock copolymer such as poloxymer P188 with adipocytes or adipose tissue to be transplanted into a subject is thought to stabilize the membranes of the cells leading to more successful fat transplantation in soft tissue reconstruction or augmentation. Such methods may also be used in the transplantation of adult stem cells or other cells derived from fat tissue. Other agents such as lipoic acid may also be added to the polymer/cell compositions for cell transplantation. | 12-19-2013 |
20130331432 | METABOLIC GENE, ENZYME, AND FLUX TARGETS FOR CANCER THERAPY - A novel pathway in cancer cell metabolism is identified. Targeting of any gene, protein, or enzyme that modulates activity or flux through this pathway, including, but not limited to IDH1, isocitrate dehydrogenase 2 (IDH2), aconitase 1 (ACO1), aconitase 2 (ACO2), glutaminase (GLS), glutamate dehydrogenase (GDH) and transaminase, provides effective means of inhibiting tumor growth. | 12-12-2013 |
20130224155 | COMPOSITIONS OF MICROBIOTA AND METHODS RELATED THERETO - Methods and compositions are generally provided for treating metabolic disorders, e.g., obesity. One aspect discloses methods and compositions for obtaining a biological sample from the subject, evaluating the sample for the presence or absence of a genetic indicator, wherein the genetic indicator is selected from a single nucleotide polymorphism and a level of gene expression, and performing a first metabolic procedure if the genetic indicator is present, or performing an alternative second metabolic procedure if the genetic indicator is absent. One aspect discloses methods and compositions for obtaining a sample including deoxyribonucleic acids (DNA) from the subject, evaluating the DNA for an absence or presence of one or more genetic indicators and performing a first metabolic procedure or an alternative second metabolic procedure based on the absence or presence of the genetic indicator(s). Other aspects are also disclosed. | 08-29-2013 |
20130217027 | AGENTS PROVIDING CONTROLS AND STANDARDS FOR IMMUNO-PRECIPITATION ASSAYS - Control agents for immuno-precipitation assays, methods of using the control agents and kits comprising the control agents are provided. | 08-22-2013 |
20130202559 | Use of Microvesicles in the Treatment of Medical Conditions - This invention relates generally to populations of microvesicles containing or otherwise associated with viral particles, methods of producing these purified populations, and methods of using these purified populations in a variety of diagnostic, therapeutic and/or prophylactic indications. | 08-08-2013 |
20130116218 | METHODS AND COMPOSITIONS OF BILE ACIDS - Methods and compositions are provided for treating metabolic disorders by modulating bile acid levels. Generally, the methods and compositions can modulate bile acid levels, such as serum bile acid levels, to treat a metabolic disorder. In one embodiment, a method of modulating a bile acid level includes measuring a bile acid level and delivering a composition effective to modulate the bile acid level. A method for modulating a bile acid profile includes comparing a bile acid profile to a target profile and delivering a bile acid cocktail to increase bile acid levels. In another embodiment, a pharmaceutical composition for increasing bile acid levels includes a bile acid cocktail effective to increase bile acid levels. The composition is further useful as part of an implantable system. | 05-09-2013 |
20130022994 | REGULATION OF BACE DEGRADATION - The invention relates to methods and products for diagnosing, preventing, and treating Alzheimer's disease and abnormal production of amyloid β. | 01-24-2013 |
20130018477 | Methods and Devices for Knee Joint Replacement with Anterior Cruciate Ligament Substitution - Methods and devices are provided for knee joint replacement with anterior cruciate ligament (ACL) substitution. Generally, the methods and devices can allow a knee joint to be partially or totally replaced in conjunction with substitution of the knee joint's ACL. In one embodiment, a knee replacement prosthesis can include a medial or lateral femoral implant, a femoral intercondylar notch structure, a medial or lateral tibial insert, and an ACL-substitution member. The ACL-substitution member can be configured to engage with the femoral intercondylar notch structure during a full range of knee motion and/or during only early knee flexion. | 01-17-2013 |
20120330236 | SINGLE-DOSE SYRINGE DRIVER - Various methods and devices for driving fluid from a syringe are provided. In one exemplary embodiment, a luer fitting for connecting a syringe barrel to a syringe driver is provided that includes a proximal female end including a socket adapted to be removably mated to a male luer fitting on the syringe barrel. The luer fitting further includes a distal end including a nozzle adapted to receive a fluid conduit. The distal end has a non-threaded axially-oriented annular socket formed therein for removably receiving a protrusion on the syringe driver. | 12-27-2012 |
20120310362 | IMPLANT FOR RESTORING NORMAL RANGE FLEXION AND KINEMATICS OF THE KNEE - Embodiments of the invention provide knee prostheses which more faithfully and closely replicate the function, anatomy and physiology of the normal human knee yielding a number of advantages. Among other things, such prostheses can provide an increased range of motion and function more normally particularly in extension, deep flexion and during normal gait. Knee prostheses according to various aspects of the invention recognize that during movement of the knee, particularly during flexion, the kinematics of the bones of the knee are a result of achieving equilibrium of the forces that cause motion of the knee. In addition, the shape of the articular surfaces acting in combination with forces imposed by various muscles, ligaments and tendons, determines the direction of the large contact forces. | 12-06-2012 |
20120296263 | TOPICAL AMINOLEVULINIC ACID-PHOTODYNAMIC THERAPY FOR THE TREATMENT OF ACNE VULGARIS - Light treatments of sebaceous gland disorders with 5-aminolevulinic acid and photodynamic therapy are disclosed. A preferred treatment includes topical application of 5-aminolevulinic acid to the skin followed by light exposures with repeated treatment at various intervals. At low doses of ALA and photodynamic therapy (PDT) in single or multiple treatments, improvement in the sebaceous gland disorder, e.g., acne, provides the discovery that diminishment in sebum secretion and the eradication of bacteria occurs. At high doses of ALA and a single high energy PDT treatment, permanent changes to the sebaceous gland and sebum secretion have been discovered. | 11-22-2012 |
20120251506 | METHODS AND COMPOSITIONS RELATING TO NEURONAL CELL AND TISSUE DIFFERENTIATION - The invention relates to methods for isolating and purifying specific types of neurons, such as cortical or other projection neurons including corticospinal motor neurons, subcerebral projection neurons, and callosal projection neurons. The invention also relates to genes that are specific for particular neuronal subtypes, and the use of such genes in genetic/molecular control of cell development. The isolated cells and subtype-specific genes also have uses in diagnostics, therapeutics, and screening assays for pharmaceutical molecules. | 10-04-2012 |
20120225130 | COMPOSITIONS, METHODS, AND DEVICES FOR TREATING LIVER DISEASE - Described are compositions and methods for treating liver disease, e.g., acute liver disease, using bone marrow-derived stem cells and bone marrow-derived stem cell conditioned media. | 09-06-2012 |
20120215321 | METHODS FOR MAKING OXIDATION RESISTANT POLYMERIC MATERIAL - The present invention relates to methods for making oxidation resistant medical devices that comprise polymeric materials, for example, ultra-high molecular weight polyethylene (UHMWPE). The invention also provides methods of making antioxidant-doped medical implants, for example, doping of medical devices containing cross-linked UHMWPE with vitamin E by diffusion and materials used therein. | 08-23-2012 |
20120202753 | INHIBITING INFLAMMATION WITH MILK OLIGOSACCHARIDES - A method of inhibiting inflammation in a subject comprising the administration of milk oligosaccharides or glycoconjugates containing milk oligosaccharides is disclosed. | 08-09-2012 |
20120202742 | METHODS AND DEVICES FOR THE SUSTAINED RELEASE OF MULTIPLE DRUGS - The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman. | 08-09-2012 |
20120191010 | PERIPHERAL BLOOD SAMPLING METHODS AND DEVICES - Methods and devices are provided for transporting fluid between a body and an external source. More particularly, the methods and devices provided can be used to transport blood from a body. In one exemplary embodiment, a system is provided for transporting fluid between a body and an external source. The system can include a collection catheter that is sized to fit inside a catheter that is placed in the body and configured to have its distal end extend beyond a distal end of the catheter that is placed in the body. Various methods for transporting fluid from the body to an external source are also provided. | 07-26-2012 |
20120177618 | HEMATOPOIETIC STROMAL PROGENITOR CELLS AND USES THEREOF - The invention provides compositions and methods for modulating disease using hematopoietic stromal progenitor cells derived from hematopoietic tissues. The invention further provides methods for isolating, storing and culturing hematopoietic stromal progenitor cells. | 07-12-2012 |
20120149592 | Compositions And Methods For Assessing Cytotoxicity Of Single Cells - The invention provides a method of analyzing interactions between pairs of target and effector cells utilizing high-throughput screenings methods for profiling large numbers of single cells in microarrays. | 06-14-2012 |
20120136258 | Retinal Flow Cytometry - The present invention provides methods and devices for performing flow cytometry. In one embodiment, blood circulating through one or more retinal blood vessels of a subject is illuminated in-vivo so as to excite a plurality of fluorescent-labeled cells contained in the blood. The fluorescence radiation emitted by the excited cells is then detected and analyzed to count the cells from which fluorescence is detected. | 05-31-2012 |
20120128641 | METHODS AND COMPOSITIONS FOR IMPROVING THE VIABILITY OF CRYOPRESERVED CELLS - The present invention provides polymers and methods for increasing the viability of cryopreserved cells after thawing. Thawing cryopreserved cells in the presence of a polymer such as poloxymer P1 88 or other non-ionic polymers is thought to stabilize the membranes of the cells leading to increased post-thaw viability. Such methods may be used in the processing of cells and tissues for transplantation or for research purposes. Other agents such as antioxidants, vitamins, or osmotic protectants may also be added to cells to improve viability. | 05-24-2012 |
20120114635 | ANTIBODIES TO CROSS-LINKED AMYLOID BETA OLIGOMERS - The invention relates to antibodies that bind cross-linked amyloid β oligomers, and methods for using such antibodies for diagnosis and treatment of Alzheimer's disease. | 05-10-2012 |
20120101147 | INHIBITION OF HDAC2 TO PROMOTE MEMORY - The invention relates to methods and products for enhancing and improving recovery of lost memories. In particular the methods are accomplished by inhibiting HDAC2 and or selectively inhibiting HDAC1/2 or HDAC1/2/3. | 04-26-2012 |
20120083862 | HEADS FOR DERMATOLOGY TREATMENT - Methods and apparatus for dermatology treatment are provided which involve the use of continuous wave (CW) radiation, preheating of the treatment volume, precooling, cooling during treatment and post-treatment cooling of the epidermis above the treatment volume, various beam focusing techniques to reduce scattering and/or other techniques for reducing the cost and/or increasing the efficacy of optical radiation for use in hair removal and other dermatological treatments. A number of embodiments are included for achieving the various objectives indicated above. | 04-05-2012 |
20120046341 | FUS/TLS-BASED COMPOUNDS AND METHODS FOR DIAGNOSIS, TREATMENT AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED MOTOR NEURON DISEASES - The invention provides novel FUS/TLS nucleic acids and proteins that comprise one or more genetic markers (for example, single nucleotide polymorphisms) and methods of use thereof including methods relating to the diagnosis of ALS or other related motor neuron disease by virtue of the presence of the mutant FUS/TLS sequence(s). | 02-23-2012 |
20120039909 | EPIGENETIC MECHANISMS RE-ESTABLISH ACCESS TO LONG-TERM MEMORY AFTER NEURONAL LOSS - The invention relates to methods and products for enhancing and improving recovery of lost memories. In particular the methods are accomplished through the increase of histone acetylation. | 02-16-2012 |
20120029065 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS - Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively. | 02-02-2012 |
20120020929 | METHODS AND COMPOSITIONS RELATING TO NEURONAL CELL AND TISSUE DIFFERENTIATION - The invention relates to methods for isolating and purifying specific types of neurons, such as cortical or other projection neurons including corticospinal motor neurons, subcerebral projection neurons, and callosal projection neurons. The invention also relates to genes that are specific for particular neuronal subtypes, and the use of such genes in genetic/molecular control of cell development. The isolated cells and subtype-specific genes also have uses in diagnostics, therapeutics, and screening assays for pharmaceutical molecules. | 01-26-2012 |
20120015382 | DROPLET-BASED SELECTION - The present invention generally relates to fluidic droplets, and techniques for screening or sorting such fluidic droplets. In some embodiments, the fluidic droplets may contain cells (e.g., hybridoma cells) that can secrete various species, such as antibodies, for example. In one aspect, a plurality of fluidic droplets containing cells is screened to determine proteins, antibodies, polypeptides, peptides, nucleic acids, or the like. For example, cells able to secrete species such as antibodies may be selected according to certain embodiments of the invention. Examples of such cells include, for instance, immortal cells such as hybridomas, or non-immortal cells such as B-cells. For instance, blood cells may be encapsulated within a plurality of fluidic droplets, and the cells able to produce antibodies may be determined. In some cases, expression or secretion levels may be determined using signaling entities, for example, determinable microparticles present within the fluidic droplet. Other aspects of the invention relate to kits involving such fluidic droplets, methods of promoting the making or use of such fluidic droplets, and the like. | 01-19-2012 |
20110270360 | METHODS AND DEVICES FOR ACTIVATING BROWN APIDOSE TISSUE USING ELECTRICAL ENERGY - Methods and devices are provided for activating brown adipose tissue (BAT). Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss. In one embodiment, a medical device is provided that activates BAT by electrically stimulating nerves that activate the BAT and/or electrically stimulating brown adipocytes directly, thereby increasing thermogenesis in the BAT and inducing weight loss through energy expenditure. | 11-03-2011 |
20110263490 | Diagnostic Methods and Combination Therapies Involving MC4R - Methods and therapeutics are provided for treating metabolic disorders by activation of melanocortin signaling pathways. Generally, the methods and therapeutics can induce activation of melanocortin receptor signaling to increase energy expenditure and induce weight loss. In one embodiment, a method for performing a diagnostic procedure can be chosen, energy expenditure then assess in light of the diagnostic procedure and a definitive procedure(s) can be selected dependent on the outcome of the energy assessment. In another embodiment, a diagnostic procedure can be chosen to activate melanocortin receptor pathways, energy expenditure can be assessed and a definitive procedure(s) can be chosen that selectively and optimally activate melanocortin receptor pathways. | 10-27-2011 |
20110177032 | USE ON ONCOLYTIC HERPES VIRUSES FOR KILLING CANCER STEM CELLS - The invention, in some aspects, relates to the selective killing of cancer stem cells by oncolytic Herpes virus mediated oncolysis. In some aspects, the invention relates to methods for treating a subject having a cancer stem cell by administering to the subject an oncolytic Herpes virus. In other aspects, the invention provides methods for evaluating the efficacy of an oncolytic Herpes virus for killing cancer stem cells. | 07-21-2011 |
20110150845 | METHODS AND COMPOSITIONS FOR MODULATING IMMUNOLOGICAL TOLERANCE - The invention provides compositions and methods for modulating immune responses using mesenchymal stem cells. The invention further provides methods for inducing tolerance to self antigens using mesenchymal stem cells. | 06-23-2011 |
20110137230 | Method and Apparatus for Medical Treatment Utilizing Long Duration Electromagnetic Radiation - A method and apparatus are provided for performing a medical procedure on a patient, for example a dermatological procedure, by use of electromagnetic radiation (EMR) having a relatively low peak power, and in particular a peak power low enough so as not to result in a phase change in the heater or chromophore absorbing radiation which would result in a significant reduction in its absorption, and of relatively long duration which is generally greater than, sometimes significantly greater than, the thermal relaxation time of the irradiated target. | 06-09-2011 |
20110092908 | SINGLE-DOSE SYRINGE DRIVER - Various methods and devices for driving fluid from a syringe are provided. In one exemplary embodiment, a syringe driver is provided having a frame that is adapted to seat a syringe, a driver that is slidably disposed within the frame and that is adapted to seat a plunger of a syringe, and a puller that is slidably disposed within the frame and that has a latch formed thereon for mating to an engagement element on the frame. The device can also include a force-delivery element, such as a constant force spring, that is coupled to and extends between the driver and the puller. In use, the puller is movable between a first position, in which the force-delivery element is in a resting position, and a second position, in which the latch on the puller mates to the engagement element on the frame to expand the force-delivery element thereby causing the force-delivery element to pull the driver and drive a plunger into a barrel of a syringe seated within the frame to deliver fluid from the syringe to a patient at a constant rate. | 04-21-2011 |
20110077216 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OTHER RELATED DISEASES - The present invention provides compositions and methods for the treatment of atherosclerosis and other related diseases. In some embodiments, a method comprises providing a composition and forming a coating of the composition on at least a portion of the interior and/or exterior surface of a tissue lumen or other body surface. The composition may remain associated with the tissue lumen or other body surface even in the presence of a strong flow of a fluid (e.g., blood flow in a blood vessel). The composition may associate with the tissue lumen via a plurality of covalent bonds. In some cases, the compositions may comprise at least one additive, for example, a therapeutically active agent or an imaging agent. | 03-31-2011 |
20110060047 | APPROACHES TO TREAT CANCER USING HB-EGF INHIBITORS - The invention provides methods for the treatment of cancer in a subject by the administration of myrsinoic acid A and/or one or more myrsinoic acid A analogs. | 03-10-2011 |
20100316679 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS - Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively. | 12-16-2010 |
20100233092 | IN-VIVO MONITORING OF CIRCULATING APOPTOTIC CELLS - The present invention provides methods and systems for performing in vivo flow cytometry. In one embodiments, selected circulating cells of interest of a subject are labeled with fluorescent probe molecules. The labeled cells are irradiated in-vivo so as to excite the fluorescent probes, and the radiation emitted by the excited probes is detected, preferably confocally. The detected radiation is then analyzed to derive desired information, such as relative cell count, of the cells of interest. In some embodiments, the circulating cells comprise apoptotic cells whose detection can allow, e.g., non-invasive monitoring of the efficacy of a cancer treatment, such as an anti-tumor or an anti-angiogenic therapy. | 09-16-2010 |
20100228326 | HEADS FOR DERMATOLOGY TREATMENT - Methods and apparatus for dermatology treatment are provided which involve the use of continuous wave (CW) radiation, preheating of the treatment volume, precooling, cooling during treatment and post-treatment cooling of the epidermis above the treatment volume, various beam focusing techniques to reduce scattering and/or other techniques for reducing the cost and/or increasing the efficacy of optical radiation for use in hair removal and other dermatological treatments. A number of embodiments are included for achieving the various objectives indicated above. | 09-09-2010 |
20100174223 | METHOD AND APPARATUS FOR OPTICAL INHIBITION OF PHOTODYNAMIC THERAPY - A system and method are provided for preventing damage to the epidermis or other epithelial or non-target tissue during photodynamic therapy treatment. For example, an inhibiting radiation can be used to control formation of a photosensitizer from a precursor photosensitizer in the epidermis or epithelial tissue. Subsequent application of a treatment radiation can activate the photosensitizer to damage or destroy target sites while the non-target tissue remains substantially unaffected. | 07-08-2010 |
20100098677 | Methods and Devices for Epithelial Protection During Photodynamic Therapy - Methods for preventing damage to the epidermis during PDT induced using a pre-photosensitizing agent are provided. The methods of the present invention utilize spatial confinement to control formation of a photoactive species from a topically-applied pre-photosensitizing agent. In one embodiment, thermal inhibition is used to prevent the metabolism of a pre-photosensitizing agent in epithelial tissue surrounding a treatment site. In another embodiment, a chemical inhibitor can be applied to the epithelial tissue to inhibit the conversion of a pre-photosensitizing agent into a phototoxic species. | 04-22-2010 |
20100082101 | HIGHLY CRYSTALLINE POLYETHYLENE - The present invention relates to methods for making highly crystalline polymeric material, for example, highly crystalline cross-linked and not cross-linked ultra-high molecular weight polyethylene (UHMWPE). The invention also provides methods of making additive-doped highly crystalline polymeric material using high pressure and high temperature crystallization processes, medical implants made thereof, and materials used therein. | 04-01-2010 |
20090299268 | Topical Aminolevulinic Acid-Photodynamic Therapy for the Treatment of Acne Vulgaris - Light treatments of sebaceous gland disorders with 5-aminolevulinic acid and photodynamic therapy are disclosed. A preferred treatment includes topical application of 5-aminolevulinic acid to the skin followed by light exposures with repeated treatment at various intervals. At low doses of ALA and photodynamic therapy (PDT) in single or multiple treatments, improvement in the sebaceous gland disorder, e.g., acne, provides the discovery that diminishment in sebum secretion and the eradication of bacteria occurs. At high doses of ALA and a single high energy PDT treatment, permanent changes to the sebaceous gland and sebum secretion have been discovered. | 12-03-2009 |
20090274654 | METHODS AND DEVICES FOR THE SUSTAINED RELEASE OF MULTIPLE DRUGS - The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman. | 11-05-2009 |
20090222019 | IMPLANT INSERTION DEVICE - Methods and devices are provided for measuring and/or controlling an amount of force applied to an implant or other element. In certain exemplary embodiments, an implant inserter tool is provided that includes a shaft having a proximal end that is adapted to receive a force and a distal end that is adapted to contact an implant. The inserter tool also include a force controlling element coupled to the shaft. In use, the distal end of the tool can be placed in contact with an implant or other element, and a force can be applied to the proximal end of the tool to drive the implant or other element into bone. The force controlling element can measure the amount of force applied to the inserter tool, thereby measuring the force applied to the implant or other element. | 09-03-2009 |
20090210066 | ANTERIOR CRUCIATE LIGAMENT SUBSTITUTING KNEE REPLACEMENT PROSTHESIS - There is disclosed a total knee replacement prosthesis, which can substitute the function of an anterior and/or a posterior cruciate ligament. A femoral component containing two intercondylar surfaces and an intercondylar region, a tibial component having a tibial platform and a bearing component, and a protrusion from the bearing component also are disclosed. | 08-20-2009 |
20090088766 | Distraction Osteogenesis Methods and Devices - Methods and devices for distraction osteogenesis are disclosed employing an energy storage device and a controlled release of energy to provide a separating force. For example, bone expansion devices can include a first anchor element attachable to a first segment of bone, a second anchor element attachable to a second segment of bone, and an actuator for applying a separating force between the first and second anchor elements. The actuator can include a potential energy storage device and a controller for releasing energy from the energy storage device to provide the separating force. | 04-02-2009 |
20090060982 | METHODS AND DEVICES FOR THE SUSTAINED RELEASE OF MULTIPLE DRUGS - The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman. | 03-05-2009 |
20090024193 | Method And Apparatus For Photothermal Treatment Of Tissue At Depth - The present invention provides method and apparatus for treating tissue in a region at depth by applying optical radiation thereto of a wavelength able to reach the depth of the region and of a selected relatively low power for a duration sufficient for the radiation to effect the desired treatment while concurrently cooling tissue above the selected region to protect such tissue. Treatment may be enhanced by applying mechanical, acoustic or electrical stimulation to the region. | 01-22-2009 |
20090014360 | SYSTEMS AND METHODS FOR PARTICLE FOCUSING IN MICROCHANNELS - Various systems, methods, and devices are provided for focusing particles suspended within a moving fluid into one or more localized stream lines. The system can include a substrate and at least one channel provided on the substrate having an inlet and an outlet. The system can further include a fluid moving along the channel in a laminar flow having suspended particles and a pumping element driving the laminar flow of the fluid. The fluid, the channel, and the pumping element can be configured to cause inertial forces to act on the particles and to focus the particles into one or more stream lines. | 01-15-2009 |
20090012354 | SYSTEM AND METHOD FOR INTRAVENTRICULAR TREATMENT - Various methods and devices are provided for remodeling a heart's ventricular walls and improving of the function of the atrioventricular valves from within the ventricle or atrium through the use of tensioning structures. In one embodiment, a device for stabilizing a ventricle is provided and can include a superior tension member having a substantially arcuate shape that is sized and configured to improve a functioning of atrioventricular valve leaflets. The device can also include a descending tension member extending inferiorly from at least a portion of the superior tension member that is shaped to correspond to a wall of a ventricular cavity. The device can further include a plurality of anchors provided at least on the descending tension member that have attachment features for holding a wall of a ventricular cavity to the descending tension member. | 01-08-2009 |
20080286339 | METHODS AND DEVICES FOR THE SUSTAINED RELEASE OF MULTIPLE DRUGS - The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman. | 11-20-2008 |
20080286322 | METHODS AND DEVICES FOR THE SUSTAINED RELEASE OF MULTIPLE DRUGS - The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman. | 11-20-2008 |
20080269608 | Non-Invasive Treatment of Fascia - Various methods and devices for minimally invasive treatment and prevention of conditions of the fascia are provided. In one aspect, a method includes providing an acoustic wave source effective to deliver a focused acoustic wave to a target site within a patient's body, and focusing an acoustic wave through a patient's skin such that at least one location in the patient's fascia is fenestrated in a desired pattern. | 10-30-2008 |
20080262120 | SELECTIVE, CONTROLLED MANIPULATION OF POLYMERS - The present invention provides partial and complete shielding approaches to alter the cross-linking characteristics of irradiated polymers, such as polyethylene. Irradiated polymers and fabricated articles, such as medical prosteses, comprising irradiated polymers also are provided. | 10-23-2008 |
20080216843 | METHODS AND DEVICES FOR RELIEVING UPPER AIRWAY OBSTRUCTIONS - Methods and devices are provided that are effective to remove an obstruction in a human airway related to snoring and/or OSA. In one embodiment, the device includes mouthpiece having a hollow body configured to be disposed in a user's mouth. The body includes superior and inferior outer surfaces as well as anterior and posterior surfaces, a channel configured to receive a user's teeth formed in at least one of the superior and inferior surfaces, an inner cavity formed between the superior, inferior, anterior, and posterior surfaces, and at least one aperture formed in the posterior surface that extends into the inner cavity. In one exemplary embodiment the at least one aperture is oriented to extend away from the user's teeth and toward a user's tongue when the mouthpiece is in use. In another embodiment, the hollow body is substantially c-shaped, and the at least one aperture includes a plurality of apertures spaced a distance apart from one another along the posterior surface between first and second terminal ends of the c-shaped inner portion of the hollow body. In still another embodiment, the mouthpiece includes an outer portion having an opening extending therethrough such that the outer portion is coupled to the hollow body and is in fluid communication with the cavity in the hollow body. A one-way valve can be disposed in the opening and can be configured to allow air to flow out of a user's oral cavity when the mouthpiece is in use. | 09-11-2008 |
20080215142 | CROSS-LINKING OF ANTIOXIDANT-CONTAINING POLYMERS - The present invention relates to methods for making cross-linked, oxidatively stable, and highly crystalline polymeric materials. The invention also provides methods of treating irradiation-cross-linked antioxidant-containing polymers and materials used therewith. | 09-04-2008 |
20080214692 | OXIDATION RESISTANT HOMOGENIZED POLYMERIC MATERIAL - The present invention relates to methods for making oxidation resistant homogenized polymeric materials and medical implants that comprise polymeric materials, for example, ultra-high molecular weight polyethylene (UHMWPE). The invention also provides methods of making antioxidant-doped medical implants, for example, doping of medical devices containing, cross-linked UHMWPE with vitamin E by diffusion and annealing the antioxidant doped UHMWPE in a super critical fluid, and materials used therein. | 09-04-2008 |